Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12111894 | 0.73 | — | — | |
| SCHEMBL9176037 | 0.71 | — | — | |
| SCHEMBL11469968 | 0.68 | — | — | |
| SCHEMBL391856 | 0.67 | LMNA (0.36) | KMT2A | |
| SCHEMBL5962443 | 0.64 | ALDH1A1 (0.54) | POLBALDH1A1RAB9AMAPK1GAA | |
| SCHEMBL10708052 | 0.61 | MAOA (0.44) | ALDH1A1MAPK1GAAL3MBTL1VCP | |
| SCHEMBL28724966 | 0.60 | — | — | |
| SCHEMBL4040587 | 0.60 | — | — | |
| SCHEMBL13735073 | 0.58 | POLB (0.51) | POLBALDH1A1GAAVCPKDM4E | |
| SCHEMBL13734677 | 0.58 | POLB (0.51) | POLBALDH1A1VCPKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2037928-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | Amgen Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | POLB 2704/4885ALDH1A1 2876/4885RAB9A 4276/4885 |
| US-20080096900-A1 | Methods for treating atherosclerosis | LCAT, PCSK9, CETP | POLB 2704/4885ALDH1A1 2876/4885RAB9A 4276/4885 |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | POLB 2704/4885ALDH1A1 2876/4885RAB9A 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.